

SFRT and SCART in Radiotherapy for Bone Metastases With Soft Tissue

NCT06987370

Status	RECRUITING
Phase	Not Applicable
Sponsor	Shandong Cancer Hospital and Institute
Enrollment	90 participants

Key Eligibility Criteria

Inclusion (10)

- 1. Sign a written informed consent form before implementing any trial-related procedures;
- 2. Male or female, aged 18 years or above and 75 years or below;
- 3. Have a histopathologically confirmed single primary tumor (patients with a pathological diagnosis of small cell carcinoma or undifferentiated carcinoma are excluded);
- 4. ECOG PS 0-2;
- 5. Have at least one target lesion: bone metastasis with a soft tissue mass confirmed by CT or MRI. The shortest diameter of the soft tissue is greater than 30mm;
- 6. The number of metastatic lesions is ≤ 5 and the number of metastatic organs is ≤ 3 ;
- 7. The expected survival time is ≥ 3 months;
- 8. The main organ functions are normal (within 14 days before enrollment), that is, the following criteria are met:
 - The blood routine examination criteria should meet:
 - Hemoglobin (HB) ≥ 90 g/L;
 - Absolute neutrophil count (ANC) $\geq 1.5 \times 10^9$ /L;
 - Platelet count (PLT) $\geq 75 \times 10^9$ /L;
- ... and 5 more (see full listing online)

Exclusion (6)

- Pathological fracture confirmed by CT or MR.
- Prior radiotherapy to the target lesion.
- Pregnant or lactating women.
- Acute infection or other serious underlying diseases.
- Obvious history of neurological and mental diseases, including dementia that may affect the ability to understand and give informed consent.
- ... and 1 more (see full listing online)

Locations (1 total)

Shandong Cancer Hospital and Institute, Jinan, Shandong, China